Cardiovascular risk in patients with inflammatory arthritis

Cover Page

Cite item

Full Text

Abstract

Rheumatoid and other inflammatory arthritis (ankylosing spondylitis and psoriatic arthritis) have a high risk of cardiovascular disease (CVD). It is caused by the accelerated development of atherosclerosis associated with a chronic systemic inflammatory process. Nevertheless, traditional CVD risk factors (hypertension, smoking, dyslipidemia) are also important for patients with inflammatory arthritis. The greatest amount of data has been accumulated regarding the relationship between CVD and rheumatoid arthritis. Due to the difficulties in diagnosing coronary heart disease and other CVD, it is of great importance to identify patients at high and very high risk. The use of scales for assessing the total cardiovascular risk SCORE/SCORE 2 with a coefficient of 1.5 allows to identify patients who need measures to reduce their high risk of CVD. Control of the of the disease activity, lifestyle modification, therapy with statins and antihypertensive drugs in accordance with current guidelines, caution when prescribing non-steroidal anti-inflammatory drugs and minimizing the dose of glucocorticoids are the main components of the strategy for reducing the risk of CVD in patients with inflammatory arthritis.

About the authors

D. A. Anichkov

Acad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Rheumatic Diseases Research Laboratory N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Author for correspondence.
Email: d.anichkov@gmail.com
ORCID iD: 0000-0001-5610-4819

Dmitry Alexandrovich Anichkov

Ostrovityanova St., Moscow 117997

1 Ostrovityanova St., Moscow 117997

Russian Federation

N. A. Shostak

Acad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-4669-1006

1 Ostrovityanova St., Moscow 117997

Russian Federation

V. T. Timofeev

Acad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Rheumatic Diseases Research Laboratory N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-3805-5942

Ostrovityanova St., Moscow 117997

1 Ostrovityanova St., Moscow 117997

Russian Federation

References

  1. Schattner A. The Cardiovascular burden of rheumatoid arthritis – implications for treatment. Am J Med 2023;136(12):1143–6. doi: 10.1016/j.amjmed.2023.09.004
  2. Masoud S., Lim P.B., Kitas G.D., Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol 2017;9(7):562–73. doi: 10.4330/wjc.v9.i7.562
  3. Agca R., Heslinga S.C., Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76(1):17–28. doi: 10.1136/annrheumdis-2016-209775
  4. Matteson E.L., Mankad R. Assessment of cardiovascular risk in patients with rheumatoid arthritis. J Rheumatol 2016;43(11):1947–9. doi: 10.3899/jrheum.161025
  5. Avina-Zubieta J.A., Thomas J., Sadatsafavi M. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71(9):1524–9. doi: 10.1136/annrheumdis-2011-200726
  6. Barkhane Z., Zaree A., Zulfiqar S. et al. Comparison of cardiovascular outcomes in patients with and without rheumatoid arthritis: a meta-analysis of observational studies. Cureus 2023;15(6):e40348. doi: 10.7759/cureus.40348
  7. Ogdie A., Yu Y., Haynes K. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74(2):326–32. doi: 10.1136/annrheumdis-2014-205675
  8. Akhlaq A., Ali H.F., Sheikh A.B. et al. Cardiovascular diseases in the patients with psoriatic arthritis. Curr Probl Cardiol 2023;48(6):101131. doi: 10.1016/j.cpcardiol.2022.101131
  9. Bhattad P.B., Kulkarni M., Patel P.D., Roumia M. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus 2022;14(6):e25633. doi: 10.7759/cureus.25633
  10. Kim J.H., Choi I.A. Cardiovascular morbidity and mortality in patients with spondyloarthritis: a meta-analysis. Int J Rheum Dis 2021;24(4):477–86. doi: 10.1111/1756-185X.13970
  11. Hintenberger R., Affenzeller B., Vladychuk V., Pieringer H. Cardiovascular risk in axial spondyloarthritis-a systematic review. Clin Rheumatol 2023;42(10):2621–33. doi: 10.1007/s10067-023-06655-z
  12. Non-ischemic cardiology guidelines / Еd. N.A. Shostak. Moscow: GEOTAR-Media, 2009. (In Russ.).
  13. Alemao E., Cawston H., Bourhis F. et al. Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford) 2017;56(5):777–86. doi: 10.1093/rheumatology/kew440
  14. Solomon D.H., Greenberg J., Curtis J.R. et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol 2015;67(8):1995–2003. doi: 10.1002/art.39195
  15. Crowson C.S., Rollefstad S., Kitas G.D. et al; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA). Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One 2017;12(3):e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017
  16. Hollan I., Dessein P.H., Ronda N. et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev 2015;14(10):952–69. doi: 10.1016/j.autrev.2015.06.004
  17. 2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал 2022;27(7):5155. doi: 10.15829/1560-4071-2022-5155.
  18. Chodara A.M., Wattiaux A., Bartels C.M. Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches. Curr Rheumatol Rep 2017;19(4):16. doi: 10.1007/s11926-017-0643-y
  19. Choi H.K., Hernán M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359(9313):1173–7. doi: 10.1016/S0140-6736(02)08213-2
  20. Jacobsson L.T., Turesson C., Gülfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32(7):1213–8.
  21. Xu J., Xiao L., Zhu J. et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum 2022;55:152031. doi: 10.1016/j.semarthrit.2022.152031
  22. Lee J.L., Sinnathurai P., Buchbinder R. et al. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther 2018;20(1):171. doi: 10.1186/s13075-018-1669-x
  23. Solomon D.H., Reed G.W., Kremer J.M. et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67(6):1449–55. doi: 10.1002/art.39098
  24. Arts E.E., Fransen J., Den Broeder A.A. et al. Low disease activity (DAS28 ≤ 3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis 2017;76(10):1693–9. doi: 10.1136/annrheumdis-2016-210997
  25. Anichkov D.A., Shostak N.A. Rheumatoid arthritis and cardiovascular risk: perspectives of treatment with statins. Ratsionalnaia farmakoterapiia v kardiologii = Rational Pharmacotherapy in Cardiology 2005;1(3):47–53. (In Russ.). doi: 10.20996/1819-6446-2005-1-3-47-53
  26. Lv S., Liu Y., Zou Z. et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2015;33(1):69–76. PMID: 25327393
  27. Huang C.Y., Lin T.T., Yang Y.H. et al. Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with rheumatoid arthritis. Int J Cardiol 2018;253:1–6. doi: 10.1016/j.ijcard.2017.11.009
  28. Rahmadi A.R., Pranata R., Raffaello W.M. et al. The effect of statin on major adverse cardiovascular events and mortality in patients with rheumatoid arthritis – a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2022;26(9):3171–8. doi: 10.26355/eurrev_202205_28734
  29. Boytsov S.A., Pogosova N.V., Ansheles A.A. et al. Cardiovascular prevention 2022. Russian national guidelines. Rossiiskii kardiologicheskii zhurnal = Russian Journal of Cardiology 2023;28(5):5452. (In Russ.). doi: 10.15829/1560-4071-2023-5452

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Anichkov D.A., Shostak N.A., Timofeev V.T.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36931 от  21.07.2009.